Figure 1.

Reprogramming of myeloid responses to enhance antitumor immunity. Tumor tissues contain extensive infiltration of suppressive myeloid cells, such as tumor-associated macrophages (TAMs), immature dendritic cells (DCs), and granulocytic myeloid-derived suppressor cells (G-MDSCs), which inhibit antitumor activities of cytotoxic T lymphocytes (CTLs). Strategies to alleviate immune suppression mediated by these myeloid cells, such as using CSF1R inhibition or CXCR1/2 signal blockade, could reprogram these myeloid cells to activate the adaptive immune system and enhance the efficacy of immunotherapeutics to eliminate tumor cells.